Allink Biotherapeutics

Healthcare & Life Sciences

Recent Finacing

Series A

Recent Raise

$42M

Allink Biotherapeutics is a clinical-stage biotechnology company focused on developing bispecific antibodies and antibody-drug conjugates (ADCs) for global clinical applications.

Total Funding

$42M

Headquarters

Shanghai, China

Founded

2023

Website

Focus Areas

Biotechnology

Clinical-stage

Bispecific antibodies

ADC technology

Global development

Lead candidates

Investors